Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INFINITY PHARMACEUTICALS INC (INFI) Stock Price & Overview
NASDAQ:INFI • US45665G3039
Current stock price
0.0447 USD
-0.04 (-46.98%)
At close:
0.04 USD
0 (-10.51%)
After Hours:
The current stock price of INFI is 0.0447 USD. Today INFI is down by -46.98%. In the past month the price decreased by -49.26%. In the past year, price decreased by -96.66%.
INFI Key Statistics
52-Week Range0.0333 - 1.33
Current INFI stock price positioned within its 52-week range.
1-Month Range0.0333 - 0.1225
Current INFI stock price positioned within its 1-month range.
- Market Cap
- 4.057M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
INFI Stock Performance
Today
-46.98%
1 Week
-49.49%
1 Month
-49.26%
3 Months
-81.22%
Longer-term
6 Months -75.84%
1 Year -96.66%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
INFI Stock Chart
INFI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to INFI. When comparing the yearly performance of all stocks, INFI is a bad performer in the overall market: 99.69% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
INFI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INFI. INFI may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
INFI Earnings
Next Earnings DateNov 13, 2023
Last Earnings DateAug 8, 2023
PeriodQ2 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -18.35%
INFI Forecast & Estimates
6 analysts have analysed INFI and the average price target is 0.31 USD. This implies a price increase of 584.56% is expected in the next year compared to the current price of 0.0447.
For the next year, analysts expect an EPS growth of 6.16% and a revenue growth 1.89% for INFI
Analysts
Analysts43.33
Price Target0.31 (593.51%)
EPS Next Y6.16%
Revenue Next Year1.89%
INFI Financial Highlights
Over the last trailing twelve months INFI reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 5.66% compared to the year before.
Income Statements
Revenue(TTM)2.57M
Net Income(TTM)-40.95M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%17.61%
Sales Q2Q%-15.01%
EPS 1Y (TTM)5.66%
Revenue 1Y (TTM)15.88%
INFI Ownership
Ownership
Inst Owners0%
Shares90.76M
Float88.28M
Ins Owners3.33%
Short Float %N/A
Short RatioN/A
INFI Industry Overview
INFI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
INFI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INFI
Company Profile
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Company Info
IPO: 2000-07-27
INFINITY PHARMACEUTICALS INC
1100 Massachusetts Avenue, Floor 4
Cambridge MASSACHUSETTS 02138 US
CEO: Adelene Q. Perkins
Employees: 30
Phone: 16174531000.0
INFINITY PHARMACEUTICALS INC / INFI FAQ
What does INFI do?
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Can you provide the latest stock price for INFINITY PHARMACEUTICALS INC?
The current stock price of INFI is 0.0447 USD. The price decreased by -46.98% in the last trading session.
Does INFI stock pay dividends?
INFI does not pay a dividend.
What is the ChartMill rating of INFINITY PHARMACEUTICALS INC stock?
INFI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of INFINITY PHARMACEUTICALS INC (INFI)?
INFINITY PHARMACEUTICALS INC (INFI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
Can you provide the market cap for INFINITY PHARMACEUTICALS INC?
INFINITY PHARMACEUTICALS INC (INFI) has a market capitalization of 4.06M USD. This makes INFI a Nano Cap stock.